{"id":4407,"date":"2024-10-08T15:50:58","date_gmt":"2024-10-08T07:50:58","guid":{"rendered":"https:\/\/flcube.com\/?p=4407"},"modified":"2024-12-09T11:47:37","modified_gmt":"2024-12-09T03:47:37","slug":"wuhan-yzy-biopharma-grants-rights-to-cd3-epcam-antibody-m701-to-chi-ta-tianqing-pharma-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=4407","title":{"rendered":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China"},"content":{"rendered":"\n

Wuhan YZY Biopharma Co., Ltd (HKG: 2496<\/a>) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3\/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone payments.<\/p>\n\n\n\n

M701, a biopharmaceutical Class 1 new drug independently developed by YZY Biopharma, is intended for the treatment of malignant pleural effusion and malignant ascites caused by tumors. It is currently in Phase III clinical trials and is the first domestically developed CD3\/EpCAM bispecific antibody to enter clinical trial stages in China. In February 2024, M701 received approval from the National Medical Products Administration (NMPA) to proceed with Phase III registration clinical trials for malignant ascites, which have now enrolled more than half of the required patients. Additionally, M701 is undergoing a Phase II clinical trial for malignant pleural effusion caused by non-small cell lung cancer.- Flcube.com<\/a><\/p>\n\n\n\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta…<\/p>\n","protected":false},"author":1,"featured_media":4408,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[661,2658,928,137],"class_list":["post-4407","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","tag-chia-tai-tianqing-pharmaceutical","tag-cttq-pharma","tag-hkg-2496","tag-yzy-biopharma"],"yoast_head":"\nWuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3\/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone payments.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=4407\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=4407\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-08T07:50:58+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-09T03:47:37+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1200\" \/>\n\t<meta property=\"og:image:height\" content=\"720\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Wuhan YZY Biopharma Grants Rights to CD3\\\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China\",\"datePublished\":\"2024-10-08T07:50:58+00:00\",\"dateModified\":\"2024-12-09T03:47:37+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407\"},\"wordCount\":174,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/66b7116e75cbadf74904b96aa157ed0c.png\",\"keywords\":[\"Chia Tai Tianqing Pharmaceutical\",\"CTTQ Pharma\",\"HKG: 2496\",\"YZY Biopharma\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4407#respond\"]}],\"copyrightYear\":\"2024\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=4407\",\"name\":\"Wuhan YZY Biopharma Grants Rights to CD3\\\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/66b7116e75cbadf74904b96aa157ed0c.png\",\"datePublished\":\"2024-10-08T07:50:58+00:00\",\"dateModified\":\"2024-12-09T03:47:37+00:00\",\"description\":\"Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3\\\/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone payments.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=4407\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/66b7116e75cbadf74904b96aa157ed0c.png\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/10\\\/66b7116e75cbadf74904b96aa157ed0c.png\",\"width\":1200,\"height\":720,\"caption\":\"Wuhan YZY Biopharma Grants Rights to CD3\\\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=4407#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Wuhan YZY Biopharma Grants Rights to CD3\\\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China - Insight, China's Pharmaceutical Industry","description":"Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3\/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone payments.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=4407","og_locale":"en_US","og_type":"article","og_title":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=4407","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2024-10-08T07:50:58+00:00","article_modified_time":"2024-12-09T03:47:37+00:00","og_image":[{"width":1200,"height":720,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=4407#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=4407"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China","datePublished":"2024-10-08T07:50:58+00:00","dateModified":"2024-12-09T03:47:37+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=4407"},"wordCount":174,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=4407#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png","keywords":["Chia Tai Tianqing Pharmaceutical","CTTQ Pharma","HKG: 2496","YZY Biopharma"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=4407#respond"]}],"copyrightYear":"2024","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=4407","url":"https:\/\/flcube.com\/?p=4407","name":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=4407#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=4407#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png","datePublished":"2024-10-08T07:50:58+00:00","dateModified":"2024-12-09T03:47:37+00:00","description":"Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta TianQing Pharma the rights to its CD3\/EpCAM bispecific antibody, M701, in Mainland China. Chi Ta Tian Qing Pharma will pay YZY Biopharma an upfront payment of up to RMB 315 million, plus additional development milestone payments.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=4407#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=4407"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=4407#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png","width":1200,"height":720,"caption":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=4407#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Wuhan YZY Biopharma Grants Rights to CD3\/EpCAM Antibody M701 to Chi Ta TianQing Pharma in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/10\/66b7116e75cbadf74904b96aa157ed0c.png","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4407","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=4407"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4407\/revisions"}],"predecessor-version":[{"id":9380,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/4407\/revisions\/9380"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/4408"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=4407"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=4407"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=4407"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}